Alembic Pharmaceuticals Limited has secured final approval from the US Food & Drug Administration (USFDA) for its Levothyroxine Sodium Tablets USP. The approval covers multiple strengths ranging from 25 mcg to 300 mcg. This product is therapeutically equivalent to the reference drug Synthroid. The estimated market size for this medication in the United States is US$ 1,869 million for the twelve months ending March 2026.
Strategic Portfolio Expansion
Alembic Pharmaceuticals has successfully expanded its generic drug portfolio with the receipt of USFDA final approval for Levothyroxine Sodium Tablets. This medication is indicated for use as a replacement therapy for various forms of congenital or acquired hypothyroidism. Additionally, it serves as an essential adjunct to surgery and radioiodine therapy in managing thyrotropin-dependent well-differentiated thyroid cancer.
Market Opportunity and R&D Milestone
The approval marks a significant milestone for the company, targeting a substantial market segment valued at approximately US$ 1,869 million based on data from the twelve months ending March 2026. This addition strengthens Alembic’s presence in the competitive US generic pharmaceutical space. With this latest approval, the company now boasts a cumulative total of 239 ANDA approvals, comprising 220 final approvals and 19 tentative approvals, highlighting its ongoing commitment to research and global manufacturing excellence.
Source: BSE
